UFP TECHNOLOGIES INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $UFPT in the last 7 days.
No SEC Form 4 filings for $UFPT in the last 30 days.
See all $UFPT insider activity →Azenta reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B revenue, up 8.7% YoY, exceeding expectations. UFP Technologies reported $174M revenue, up 15.1% YoY, with the largest analyst estimate beat. West Pharmaceutical Services reported $872.3M revenue, up 13.8% YoY, topping expectations. All stocks have seen post-earnings gains.
Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
Argus raised its price target for UFP Technologies (UFPT) to $334, citing strong recent performance and growth prospects. The stock has gained 34.60% year-to-date and 54.03% over one year. Analysts estimate a fair value of $355, but the stock trades at a P/E of 32.2x, higher than its industry average. The company's expansion and medical sector focus drive optimism, though risks include customer concentration and integration challenges.
Recent UFPT coverage spans earnings, insider activity and financial news.
Post‑earnings price rally
No new information; article recaps other companies' earnings.
Potential upside as the market prices in the higher target.
The deal adds CI Medical's products to UFP's portfolio, potentially expanding market reach and revenue.
Earnings beat on revenue and margin expansion may support upside, but SG&A growth and cash burn raise downside risk, especially with 19% short interest.
AlphAI scores every news story that mentions UFPT with an AI model for sentiment and relevance, and aggregates insider trades from UFP TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Azenta reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B revenue, up 8.7% YoY, exceeding expectations. UFP Technologies reported $174M revenue, up 15.1% YoY, with the largest analyst estimate beat. West Pharmaceutical Services reported $872.3M revenue, up 13.8% YoY, topping expectations. All stocks have seen post-earnings gains.
2 min readAzenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
2 min readArgus raised its price target for UFP Technologies (UFPT) to $334, citing strong recent performance and growth prospects. The stock has gained 34.60% year-to-date and 54.03% over one year. Analysts estimate a fair value of $355, but the stock trades at a P/E of 32.2x, higher than its industry average. The company's expansion and medical sector focus drive optimism, though risks include customer concentration and integration challenges.
2 min readUFP Technologies, Inc. (UFPT) completed the acquisition of CI Medical Inc. on September 7, 2026. The company's stock has seen a 5-day change of 288.79 USD, a 1st Jan change of +0.79%, and a year-to-date change of +30.07%.
1 min readUFP Technologies (UFPT) reported record Q2 profits of $20.9M, up 21.4% YoY, with net sales of $174.0M, up 15.1%. Gross margin rose to 29.3%, but SG&A expenses increased 21.8%, raising concerns. CEO noted near-term margin pressure due to Dominican Republic operations. Hedge fund interest declined, and short interest is high at 19.26% of float.
3 min readUFP Technologies (UFPT) aims for 12%-18% annual growth via organic growth and acquisitions, targeting medical device markets. The company expects gross margins of 28%-31% and operating margins of 17%-20%. UFP is evaluating 5-10 acquisition opportunities with EBITDA ranging from $5M to $30M. Inventory is expected to decline in Q4 due to seasonal factors.
2 min readUFP Technologies director Marc D. Kozin sold 6,975 shares in two transactions, averaging $304.52 per share, totaling $2.13M. Kozin now owns 21,112 shares. The sales were reported in an SEC Form 4 filing.
1 min readKOZIN MARC D sold 7,000 shares of UFP TECHNOLOGIES INC (UFPT) at an average of $304.50 ($303.97–$305.07, $2.13M total) across 2 trades on 2026-08-25.
1 min readHudson Symeria sold 1,926 shares of UFP TECHNOLOGIES INC (UFPT) at $324.58 ($0.63M total) on 2026-08-14.
1 min readFELDMANN CYNTHIA L sold 1,000 shares of UFP TECHNOLOGIES INC (UFPT) at $324.26 ($0.32M total) on 2026-08-13.
2 min read
